Clinical trial Recruiting at 4 sites Interventional Ages 18 and up

MRace Implant: A first look at fixing the mitral valve to reduce regurgitation

Official title: Early Feasibility Experience of Posterior Leaflet Restoration to Reduce Mitral Regurgitation Using the MRace Implant Brazil (EXPLORE MRace - GE)

Run by Polares Medical SA · NCT07796659 · Data updated 2026-11-12

This single-arm study tests whether the MRace Implant and Delivery System can safely place a prosthesis to reduce severe mitral regurgitation in high-risk patients who may not be good candidates for open-heart surgery.

More Mitral Valve Disease trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorPolares Medical SA
Industry-sponsored
Locations4 sites (Tbilisi and 3 other locations)
StatusRecruiting
StartedMay 23, 2022
Main results expectedDecember 2032
Study endsDecember 2032
Registry record updatedSeptember 1, 2026
Trial IDNCT07796659 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18+ with greater than moderate MR (3+ or higher) who are high surgical risk but deemed operable by a local heart team.

Probably not a fit

Patients with severe tricuspid or aortic disease or those with certain anatomical factors may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early feasibility study will enroll up to 100 adults with at least moderate-to-severe mitral regurgitation who are high surgical risk. It uses a transcatheter approach to implant a posterior leaflet augmentation prosthesis via a transvenous/transseptal route, aiming to improve valve coaptation. The primary goal is to assess safety and feasibility, with follow-up extending to five years to gather preliminary performance data. The study is conducted at four centers in Georgia and Israel and is structured as a registry without a control group. Patients will receive regular post-procedure evaluations to monitor MR reduction and valve function.

Why it matters

Potential benefit: If successful, patients may experience reduced mitral regurgitation and potentially improved symptoms and quality of life without open-heart surgery.

How similar studies have gone: Prior edge-to-edge repair approaches have shown benefit in select high-risk patients; this MRace strategy is an exploratory, novel approach with limited prior clinical success data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. 18 years of age or older
2. Greater than moderate mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure
3. Patient must present with an STS Score less than 10%
4. High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure
5. New York Heart Association (NYHA) Functional Class III or IV
6. Patient willing to participate in study and provide signed IRB/EC-approved informed consent
7. Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits

Exclusion Criteria:

1. Severe tricuspid regurgitation
2. Severe aortic stenosis or insufficiency
3. Severe mitral annulus calcification
4. Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification
5. Implanted vena cava filter
6. Femoral veins with severe angulation and calcification
7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan
8. Active infection or endocarditis
9. Previous mitral valve surgery
10. Prior orthotopic heart transplantation
11. Pulmonary artery systolic hypertension \> 70mmHg
12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus
13. Left ventricular ejection fraction (LVEF) \< 20%
14. Implant or revision of any pacing device \< 30 days prior to intervention
15. Symptomatic coronary artery disease treated \< 30 days prior to study procedure
16. Myocardial infarction requiring intervention \< 30 days prior to study procedure
17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis
18. Active peptic ulcer or upper gastrointestinal bleeding \< 90 days prior to study procedure
19. Stroke \< 180 days prior to study procedure
20. Severe renal insufficiency (creatinine \> 3.0 mg/dL) or Subject requiring dialysis
21. Cardiogenic shock at time of enrollment
22. Hemodynamic instability requiring inotropic support or mechanical heart assistance
23. Concurrent medical condition with a life expectancy of less than 2 years
24. Pregnancy or breastfeeding at time of enrollment
25. History of bleeding diathesis or coagulopathy or leukopenia (WBC \< 3,000 mcL) or acute anemia (Hb \< 9 g/dL) or thrombocytopenia (platelets \< 50,000 cells mcL)
26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated
27. Emergency situations
28. Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial/procedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments
29. Company employees or their immediate family members
30. Subject is under guardianship
31. Subject is participating in another clinical study for which follow-up is currently ongoing.

Where it's running

  • Israeli-Georgian Medical Research Clinic Healthycore
    Tbilisi, Georgia
    Recruiting
  • LLC "Emergency Cardilogy Center by Acad. G. Chapidze"
    Tbilisi, Georgia
    Recruiting
  • Ltd Tbilisi Heart and Vascular Clinic
    Tbilisi, Georgia
    Recruiting
  • Ltd Tbilisi Heart Centre
    Tbilisi, Georgia
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Mitral Valve Calcification Imaging with TrueVue 3D Light Rendering

    This study tests how well three-dimensional transesophageal echocardiography with TrueVue transillumination detects mitral valve calcifications compared with CT in adults.

    Recruiting Centro Cardiologico Monzino · Milan, Milan · NCT07612553

  • Tracking progression and consequences of heart valve disease

    This project will follow adults with moderate or worse valve disease to see if clinical tests and imaging can predict when their condition will get worse.

    Recruiting at 15 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Fuzhou, Fujian and 14 other locations · NCT07267117

  • Surgical implantation of a polymer prosthetic mitral or aortic valve

    This will test a surgically implanted polymer heart valve to see if it is safe and works well for adults who need mitral or aortic valve replacement.

    Recruiting Mitrassist Lifesciences Limited Co., Ltd. · Shanghai, Shanghai Municipality · NCT07097740

  • Abbott Cephea registry for mitral valve disease

    Collects clinical information on adults with symptomatic mitral valve disease to see how correcting the valve with the Cephea system affects outcomes for patients who might be candidates for transcatheter mitral valve replacement.

    Recruiting at 24 sites Abbott Medical Devices · Birmingham, Alabama and 23 other locations · NCT07069673

  • Using the CoolCryo System to treat Atrial Fibrillation during Mitral Valve Surgery

    This study is testing whether the CoolCryo system can safely help people with atrial fibrillation feel better during mitral valve surgery.

    Recruiting at 2 sites Medinice S.A. · Bydgoszcz and 1 other locations · NCT06557616

  • Left atrial shunt to help after mitral valve surgery

    This study tests whether making a small opening between the left and right atria during mitral valve repair can relieve high left atrial pressure for adults with primary mitral regurgitation.

    Recruiting Ottawa Heart Institute Research Corporation · Ottawa, Ontario · NCT06547788

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.